Get the Stockscreener App
2.20
3.29%
0.07
After Hours:
2.20
Acumen Pharmaceuticals Inc stock is traded at $2.20, with a volume of 244.61K.
It is up +3.29% in the last 24 hours and down -6.78% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
See More
Previous Close:
$2.13
Open:
$2.19
24h Volume:
244.61K
Relative Volume:
0.56
Market Cap:
$158.90M
Revenue:
-
Net Income/Loss:
$-113.28M
P/E Ratio:
-1.1855
EPS:
-1.8557
Net Cash Flow:
$-105.55M
1W Performance:
-0.45%
1M Performance:
-6.78%
6M Performance:
-19.12%
1Y Performance:
+40.13%
1-Day Range:
$2.175
$2.25
1-Week Range:
$2.115
$2.2587
52-Week Range:
$1.1901
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.20 | 153.84M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals Inc - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.235|Chg%:+0.105 - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.100|Chg%:-0.030 - TradingKey
Price to earnings forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acumen Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock SlipsSpecial Dividend Alert - dars.gov.et
Are medical stocks lagging Acumen Pharmaceuticals (ABOS) this year? - MSN
Acumen Pharmaceuticals Presents Enhanced Brain Delivery Program Data and Early Alzheimer?S Disease Insights At Alzheimer?S Association International Conference 2026 - marketscreener.com
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy - Yahoo Finance
Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights - Yahoo Finance
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? - Yahoo! Finance Canada
Acumen Pharmaceuticals Advances Brain-Delivery Platform With New AAIC 2026 Data - t.co
Acumen Pharmaceuticals Reports Enhanced Brain Penetration of EBD Antibodies and Patient Experience Findings at AAIC 2026 - Quiver Quantitative
38 Early Alzheimer's Participants Describe Memory and Social Challenges - Stock Titan
Acumen Pharmaceuticals, Inc. promotes presence as Silver Sponsor at Alzheimer association conference in London - Traders Union
Acumen Pharmaceuticals (ABOS) Holds at Support Amid Modest Decline – Key Levels in FocusATR Trailing Stop - dars.gov.et
Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs - ACCESS Newswire
Acumen Pharmaceuticals (ABOS) Dips 2.43% as Stock Approaches Key Support LevelSweep Order Flow - dars.gov.et
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - The Manila Times
Acumen to show brain-delivery data and patient insights at AAIC 2026 - Stock Titan
Number of shareholders of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals (ABOS) Q1 2026 Earnings: Narrower Loss Beats Expectations as Alzheimer’s Pipeline AdvancesForward EPS Estimate - dars.gov.et
Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care - Traders Union
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000E Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 3000E Index - marketscreener.com
Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS) - TradingView
ABOS Forecast — Price Target — Prediction for 2027 - TradingView
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals (ABOS) Holds Steady Near $2.26 as Biotech Sector Watches for Next MoveBearish Pattern Stocks - dars.gov.et
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - BioSpace
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Insider Makes Eye-Catching Stock Move - TipRanks
Acumen Pharmaceuticals director Porter sells $75,239 in stock - Investing.com UK
Acumen Pharmaceuticals director Porter sells $75,239 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options - Stock Titan
Acumen exercises option for JCR brain technology - grafa.com
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise - Stock Titan
Acumen selects development candidates for Alzheimer’s disease - BioWorld News
Acumen nominates two Alzheimer’s candidates for development - Investing.com UK
Acumen nominates two Alzheimer’s candidates for development By Investing.com - Investing.com South Africa
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease - Yahoo Finance
ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares - Stock Titan
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):